Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Groupwide Phase II Study of Trastuzumab (Herceptin) in Metastatic Osteosarcoma Patients With Tumors That Overexpress HER2.

Trial Profile

A Groupwide Phase II Study of Trastuzumab (Herceptin) in Metastatic Osteosarcoma Patients With Tumors That Overexpress HER2.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2013

At a glance

  • Drugs Trastuzumab (Primary) ; Cisplatin; Doxorubicin; Etoposide; Filgrastim; Folinic acid; Folinic acid; Ifosfamide; Methotrexate
  • Indications Osteosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect).
    • 30 Jun 2009 Additional lead investigators identified as reported by New Jersey Cancer Trial Connect.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top